Navigation Links
New Research Validates Results of Previous Studies Demonstrating Tru-D® (Lumalier Corporation) Significantly Reduces Environmental Contamination on Surfaces in Patient Rooms
Date:8/12/2011

MEMPHIS, Tenn., Aug. 12, 2011 /PRNewswire/ -- In an original article coauthored by John M. Boyce, MD; Nancy L. Havill, MT; and Brent A. Moore, PhD, "Terminal Decontamination of Patient Rooms Using an Automated Mobile UV Light Unit" (Infection Control and Hospital Epidemiology, August 2011), the research team from the Hospital of Saint Raphael and the Yale University School of Medicine ". . . demonstrated that an automated, portable UV light device significantly reduced aerobic colony counts on high-touch surfaces in patient rooms. Two previous studies evaluated the ability of the same automated UV light device (Tru-D®; Lumalier) to decontaminate surfaces in laboratory settings and hospital rooms."

All three studies are specific to Tru-D®, a calibrated UV disinfection instrument featuring patented Sensor360™ technology that has undergone rigorous third party clinical testing on more than 100 contaminated hospital rooms under demanding, scientifically controlled conditions. Tru-D® Disinfection is not based on calculated averages or estimates. The Sensor360™ array scans the targeted space to automatically compensate for every unique variable in real time to assure confident disinfection of all environmental surfaces. Company claims have been proven to be repeatable, significantly reducing human error regardless of room configuration or content complexity.

Researchers commented that Tru-D® "was easy to use and required only a few minutes to set up. It does not require constant monitoring because the device turns itself off when a cycle has been completed and does not require sealing of air conditioning or heating vents or doors."

The article concluded that research "confirmed the results of previous studies that demonstrated that (Tru-D®) significantly reduced environmental contamination on surfaces in patient rooms." Although the assessment in the Yale study was more rigorous than previous studies, ". . . the levels of reduction in vegetative bacteria and C. difficile spores observed in our study were similar to those reported previously."

In the same ICHE Journal, the research team of William A. Rutala, PhD, MPH, and David J. Weber, MD, MPH, published a confirmation of the Boyce et al. study.

In the commentary "Are Room Decontamination Units Needed to Prevent Transmission of Environmental Pathogens?" Rutala and Weber determined after a comprehensive literature review that only Tru-D®'s automated method of measuring reflected UV dose has device-specific, evidence-based data to prove efficacy, deeming the device uniquely suitable for implementation into healthcare facilities, noting that Tru-D® "has been shown to eliminate more than 3-log vegetative bacteria (MRSA, VRE, and Acinetobacter) and more than 2.4-log C. difficile in contaminated patient rooms . . .  

"Room decontamination with the (Tru-D®) system resulted in significant reductions in aerobic bacteria . . . Boyce et al. reports the results of assessing the effectiveness of (Tru-D®) in reducing environmental contamination with vegetative bacteria and C. difficile . . ."  

The authors noted Tru-D's "ability to substantially reduce C. difficile, given that low-level disinfectants (such as quaternary ammonium compounds) have limited measurable activity against spore-forming bacteria." Tru-D's Smart UVC™ no-touch method of disinfection is chemical- and residual-free and decontaminates all exposed surfaces and equipment in the room. Other studies support Tru-D®'s ability to decontaminate surfaces in hospital rooms. After inoculating surfaces with MRSA, VRE, or C. difficile spores, Nerandzic et al.(1) found that C. difficile spores and MRSA were reduced by more than 2–4 log and VRE by more than 3–4 log.  

Researchers caution against integrating any technology into healthcare facilities without evidence-based device-specific data, and without safety certifications from Nationally Recognized Testing Laboratories such as UL or ETL.

The commentary concludes, ". . . no disinfection system should be introduced into any healthcare facility until the specific system is studied and its efficacy demonstrated . . . There is now ample evidence that no-touch systems such as (Tru-D®) . . . can reduce environmental contamination with healthcare-associated pathogens."

For information and copies of studies or to schedule a consultation, contact Chuck Dunn, President, Tru-D, LLC, at 800-774-5799, email Lumalier@lumalier.com, or visit online at http://www.Tru-D.net.  

(1) Nerandzic MM, Cadnum JL, Pultz MJ, Donskey CJ. Evaluation of an automated ultraviolet radiation system for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms. BMC Infectious Diseases 2010;10:197.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Lumalier Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Market Research Structures and Activities That Optimize Payer Access & Insights
2. Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs
3. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
4. Intercept Pharmaceuticals and Servier Announce Agreement for Intercepts TGR5 Research Program in Type 2 Diabetes
5. Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research
6. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
7. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
8. Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement
9. Rise in Emerging Infectious Disease Demands Increased Research and Health Laboratory Infrastructure in India
10. Bayer HealthCare Provides Nearly $2.5 Million to Advance Hemophilia Research and Patient Care
11. Bend Research Inc. Names New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):